SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE PSORIATIC ARTHRITIS IN ANTI-TNF-NAIVE PATIENTS AND THOSE PREVIOUSLY EXPOSED TO ANTI-TNF THERAPY: 52-WEEK RESULTS FROM A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 TRIAL WITH SUBCUTANEOUS DOSING

被引：0
|
作者：
Hall, Stephen [1 ]
Kavanaugh, Arthur [2 ]
McInnes, Iain [3 ]
Mease, Philip [4 ]
Chinoy, Hector [5 ]
Kivitz, Alan [6 ]
Patekar, Manmath [7 ]
Wang, Z. [8 ]
Mpofu, Shephard [9 ]
机构：
[1] Monash Univ, Melbourne, Vic 3004, Australia
[2] Univ Calif San Diego, Sch Med, San Diego, CA USA
[3] Univ Glasgow, Glasgow G12 8QQ, Lanark, Scotland
[4] Univ Washington, Swedish Med Ctr, Seattle, WA 98195 USA
[5] Univ Manchester, Manchester M13 9PL, Lancs, England
[6] Altoona Ctr Clin Res, Duncansville, PA USA
[7] Novartis Healthcare Pvt Ltd, Hyderabad, Andhra Pradesh, India
[8] Novartis Pharmaceut, E Hanover, NJ USA
[9] Novartis Pharma AG, Basel, Switzerland
来源：
INTERNAL MEDICINE JOURNAL | 2016年 / 46卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
ARA-P88
引用
收藏
页码：38 / 39
页数：2
相关论文
共 50 条
  • [41] INTRAVENOUS LOADING AND SUBCUTANEOUS MAINTENANCE WITH SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENT IN MULTIPLE MEASURES OF DISEASE ACTIVITY IN SUBJECTS WITH ACTIVE ANKYLOSING SPONDYLITIS: 52-WEEK DATA FROM THE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 MEASURE 1 STUDY
    Wei, J. C. C.
    Baeten, D. L.
    Geusens, P.
    Porter, B.
    Martin, R.
    Richards, H.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 1146 - 1147
  • [42] Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial
    Ritchlin, Christopher T.
    Kavanaugh, Arthur
    Merola, Joseph F.
    Schett, Georg
    Scher, Jose U.
    Warren, Richard B.
    Gottlieb, Alice B.
    Assudani, Deepak
    Bedford-Rice, Kathy
    Coarse, Jason
    Ink, Barbara
    McInnes, Iain B.
    LANCET, 2020, 395 (10222): : 427 - 440
  • [43] Bimekizumab Treatment in Biologic DMARD-Naive Patients with Active Psoriatic Arthritis: 52-Week Efficacy and Safety Results from a Phase 3, Randomized, Placebo-Controlled, Active Reference Study
    Ritchlin, Christopher
    Coates, Laura
    McInnes, Iain
    Mease, Philip J.
    Merola, Joseph
    Tanaka, Yoshiya
    Asahina, Akihiko
    Gossec, Laure
    Gottlieb, Alice
    Thaci, Diamant
    Ink, Barbara
    Assudani, Deepak
    Bajracharya, Rajan
    Shende, Vish
    Coarse, Jason
    Landewe, Robert
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 4533 - 4536
  • [44] Secukinumab, a Human Anti-Interleukin-17A Monoclonal Antibody, Improves Active Psoriatic Arthritis: 24-Week Efficacy and Safety Data from a Phase 3 Randomized, Multicenter, Double-Blind, Placebo-Controlled Study Using Subcutaneous Dosing.
    McInnes, Iain B.
    Mease, Philip J.
    Kirkham, Bruce
    Kavanaugh, Arthur
    Ritchlin, Christopher T.
    Rahman, Proton
    van der Heijde, Desiree
    Landewe, Robert B. M.
    Conaghan, Philip G.
    Richards, Hanno
    Ligozio, Gregory
    Pricop, Luminita
    Mpofu, Shephard
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 (12) : 3529 - 3529
  • [45] EFFICACY AND SAFETY OF SIRUKUMAB, AN ANTI-IL-6 CYTOKINE MONOCLONAL ANTIBODY, IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS DESPITE ANTI-TNF THERAPY: RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED GLOBAL PHASE 3 STUDY (SIRROUND-T)
    Pile, K.
    Aletaha, D.
    Tanaka, Y.
    Agarwal, P.
    Kurrasch, R.
    Tak, P.
    Popik, S.
    INTERNAL MEDICINE JOURNAL, 2017, 47 : 27 - 27
  • [46] Guselkumab, an Anti-interleukin-23p19 Monoclonal Antibody, in Biologic-naive Patients with Active Psoriatic Arthritis: Week 24 Results of the Phase 3, Randomized, Double-blind, Placebo-controlled Study
    Mease, Philip J.
    Rahman, Proton
    Gottlieb, Alice B.
    Hsia, Elizabeth
    Kollmeier, Alexa
    Xu, Xie
    Subramanian, Ramanand
    Agarwal, Prasheen
    Sheng, Shihong
    Zhou, Bei
    van der Heijde, Desiree
    McInnes, Iain
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [47] GUSELKUMAB, AN ANTI-INTERLEUKIN-23P19 MONOCLONAL ANTIBODY, IN BIOLOGIC-NAIVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: WEEK 24 RESULTS OF THE PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
    Mease, Philip J.
    Rahman, Proton
    Gottlieb, Alice
    Hsia, Elizabeth
    Kollmeier, Alexa P.
    Xu, Xie L.
    Subramanian, Ramanand A.
    Agarwal, Prasheen
    Sheng, Shihong
    Zhou, Bei
    van der Helide, Desiree
    Zazzetti, Federico
    McInnes, Lin B.
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2020, 26 : 23 - 23
  • [48] Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study
    Isenberg, D. A.
    Petri, M.
    Kalunian, K.
    Tanaka, Y.
    Urowitz, M. B.
    Hoffman, R. W.
    Morgan-Cox, M.
    Iikuni, N.
    Silk, M.
    Wallace, D. J.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 (02) : 323 - 331
  • [49] SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENT IN PHYSICAL FUNCTION, HEALTH-RELATED QUALITY OF LIFE, FATIGUE, AND WORK PRODUCTIVITY IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: 52-WEEK RESULTS FROM AN INTERNATIONAL PHASE 3 TRIAL
    Strand, Vibeke
    Rahman, Proton
    Churchill, Melvin
    Dokoupilova, Eva
    Marzo-Orteg, Helena
    McInnes, Iain B.
    Zuazo, James
    Mpofu, Shephard
    Pricop, Luminita
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2016, 22 (03) : 142 - 143
  • [50] An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP): a 52 week, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
    Warren, Richard B.
    Mrowietz, Ulrich
    von Kiedrowski, Ralph
    Niesmann, Johannes
    Wilsmann-Theis, Dagmar
    Ghoreschi, Kamran
    Zschocke, Ina
    Falk, Thomas M.
    Bloedorn-Schlicht, Norbert
    Reich, Kristian
    LANCET, 2017, 389 (10068): : 528 - 537
12345